Shots:  Clinical trial sponsors are rapidly moving toward objective, continuous respiratory monitoring, adopting technologies like the RESP Biosensor to improve endpoint sensitivity, safety assessments, and real-world patient insight.  Beyond cough frequency, emerging acoustic biomarkers, such as wheezes, crackles, cough intensity, and cough bout patterns, are redefining how respiratory function and therapeutic impact are measured in modern trials.  PharmaShots welcomes Nick Delmonico,…